RxDoctor Payments Data

Chien Ou, MD

Ophthalmology · Lewisburg, PANPI 1790916385

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 44 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$688
  • Rxsight Inc$228
  • Regeneron Healthcare Solutions, Inc.$138
  • Bausch & Lomb Americas Inc.$100
  • Carl Zeiss Meditec Cataract Technology Inc.$52
  • Oyster Point Pharma, Inc.$48
  • plus $159 from 8 others

What the payments were for

  • Food & beverage$1,39699%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,413 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$437,834
Medicare patients
1,201
Services billed
3,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate130$56,668
LumiganBimatoprost79$44,241
XiidraLifitegrast36$40,043
RestasisCyclosporine27$29,456
Brimonidine Tartrate277$28,101
VyzultaLatanoprostene Bunod33$20,699
Prednisolone Acetate273$17,230
Latanoprost846$13,549
SimbrinzaBrinzolamide/Brimonidine Tart40$12,202
RocklatanNetarsudil Mesylat/Latanoprost22$11,617
Brinzolamide25$9,690
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat345$7,647
Alphagan PBrimonidine Tartrate17$6,574
Travoprost23$4,554
Cyclosporine16$4,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$24$80,271123 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$17$68,285152 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$100$60,74269 claims
AlconSimbrinza$688$12,20240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Lewisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →